Glutamine suppresses PGE2 synthesis and breast cancer growth

Journal of Surgical Research

Volumn 63, Issue 1, 1996, Pages 293-297

  Klimberg, V Suzanne ^a,b   Kornbluth, Jacki ^b   Cao, Yihong ^a   Dang, A ^b   Blossom, Sarah ^a   Schaeffer, Robert F ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREAMINE; GLUTAMINE; GLUTATHIONE; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BODY WEIGHT; BREAST CANCER; CANCER INHIBITION; CANCER TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GLUTATHIONE METABOLISM; IMMUNOMODULATION; LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; SPLEEN; TUMOR VOLUME;

EID: 0029887479     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0263     Document Type: Conference Paper

References (39)

1. Clark, G. M., and McGuire, W. Prognostic factors in primary breast cancer. Breast Cancer Res. Treat. 3: 69-72, 1983.
2. Allegra, J., Lippman, M., Simon, R., et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat. Rep. 63: 1271-1277, 1979.
3. Herberman, R., and Ortaldo, J. R. Natural Killer cells: Their role in defenses against disease. Science 214: 24-30, 1981.
4. Trinchieri, G. B., and Perussia, B. Human natural killer cells: Biologic and pathologic aspects. Lab. Invest. 50: 489-513, 1984.
5. Levy, S., Herberman, R., Lippman, M., et al. Immunological and psychosocial, predictors of disease recurrence in patients with early stage breast cancer. Behav. Med. 17(2): 67-75, 1991.
6. Levy, S., and Herberman, R. Prognostic risk assessment in primary breast cancer by behavioral and immunologic parameters. Health Psychol. 4: 99-113, 1985.
7. Rosenberg, S. A., Lotze, M. T., Yang, J. C., et al. Experience with the use of high-dose Interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210: 474-485, 1989.
8. Rosenberg, S. A., Lotze, M. T., Muul, L. M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEJM 316: 889-897, 1987.
9. Newsholme, E. A., Crabtree, B., Ardawi, M. S. M., et al. Glutamine metabolism in lymphocytes: Its biochemical, physiological and clinical importance. Q. J. Exp. Physiol. 70: 473-489, 1985.
10. Welbourne, T. C. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can. J. Biochem. 57: 233-237, 1979.
11. Rouse, K., Nwokedi, E., Woodliff, J., Epstein, J., and Klimberg, V. S. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann. Surg. 221(4): 420-426, 1995.
12. Fahr, M., Kornbluth, J., Blossom, S., Schaeffer R., and Klimberg, V. S. Glutamine enhances immunoregulation of tumor growth. JPEN 18: 471-476, 1994.
13. Karmali, R. A. Growth inhibition and prostaglandin metabolism in the R3230AC mammary adenocarcinoma by reduced glutathione. Cancer Biochem. Biophys. 7: 147-154, 1984.
14. Buckley, B. J., Kent, R. S., and Whorton, A. R. Regulation of endothelial cell prostaglandin synthesis by glutathione. J. Biol. Chem. 266: 16659-16666, 1991.
15. Brunda, M. J., Herberman, R. B., and Holden, H. T. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124(6): 2682-2687, 1980.
16. Neri, A., Welch, D. R., Kawaguchi, T., and Nicolson, G. L. Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J. Natl. Cancer Inst. 68: 507-517, 1982.
17. Bergmeyer, H. U. (Ed.), Methods of Enzymatic Analysis, Vol. 4. New York: John Wiley & Sons, 1974. Pp. 1704-1708.
18. Tietze, F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem. 27: 502-522, 1969.
19. Anderson, M. E. Enzymatic and chemical methods for the determination of glutathione. In D. Dolphin (Ed.), Glutathione, Vol 1, New York: John Wiley & Sons, 1983. Pp. 340-365.
20. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106: 207-212, 1980.
21. Pollock, R. E., Babcock, G., Romsdahl, M. M., et al. Surgical stress suppression of murine natural killer cell cytotoxicity. Cancer Res. 44: 3888-3890, 1984.
22. Kovacevic, Z., and Morris, H. P. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 32: 326-333, 1972.
23. Knox, W. E., Linder, M., and Friedell, G. H. A series of transplantable rat mammary tumors with graded differentiation, growth rate and glutaminase content. Cancer Res. 30: 283-287, 1970.
24. Souba, W. W., Strebel, F. R., Bul, J. M., et al. Interorgan glutamine metabolism in the tumor-bearing rat. J. Surg. Res. 44: 720-726, 1988.
25. Jepson, M. M., Bates, P. C., Broadbent, P., Pell, J. M., and Millward, D. J. Relationship between glutamine concentration and protein synthesis in rat skeletal muscle. Am. J. Physiol. 255(2Pt1): E166-E172, 1988.
26. Kawamura, I., Moldawer, L. L., Keenan, R. A., et al. Altered amino acid kinetics in rats with progressive tumor growth. Cancer Res. 42: 824-829, 1982.
27. Chen, M. K., Austgen, T. R., Klimberg, V. S., Copeland, E. M., and Souba, W. W. Tumor glutamine use exceeds intestinal glutamine use in cachectic tumor-bearing rats. Surg. Forum XLI: 12-14, 1990.
28. Klimberg, V. S., Souba, W. W., Salloum, R. M., et al. Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J. Surg. Res. 48: 319-323, 1990.
29. Jensen, J. C., Schaeffer, R., Nwokedi, E., et al. Dietary Glutamine prevents chronic radiation enteropathy. Ann. Surg. Oncol. 1: 157-163, 1993.
30. Liang, C., Cattill, D., and Liang, S. Glutathione regulates interleukin-2 activity on cytotoxic T-cell. J. Biol. Chem. 264(23): 13519-23523, 1989.
31. Juretic, A., Spagnoli, G. C., Horig, H., et al. Glutamine requirements in the generation of lymphokine-activated cells. Clin. Nutr. 13: 42-49, 1994.
32. Fitzgerald-Bocarsky, P., Herberman, R., Hercend, T., et al. A definition of natural killer cells. Immunol. Today 9: 292, 1988.
33. Ortaldo, J. R., Mason, A. T., Gerald, J. P., et al. Effects of natural and recombinant IL-2 on regulation of IFN gamma production and natural killer activity: Lack of involvement of Tac antigen for these immunoregulatory effects. J. Immunol. 133: 779-783, 1984.
34. Ortaldo, J. R., Mason, A., and Overton, R. Lymphokine-activated killer cells: Analysis of progenitors and effectors. J. Exp. Med. 164: 1193-1205, 1986.
35. Introna, M., and Montovani, A. Natural killer cells in human solid tumors. Cancer Metastasis Rev. 2: 337-350, 1983.
36. Habu, S., Fukui, H., Shimamura, K., et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127: 34-38, 1981.
37. Habu, S., Cunningham-Rundles, S., Flippa, D. A., et al. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. JNCI 67: 585-590, 1981.
38. Strayer, D. R., Carter, W. A., Mayberry, S. D., Pequignot, E., and Brodsky, F. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res. 44: 370-374, 1984.
39. Baxevanis, C. N., Reclos, G. J., Gritzapis, A. D., et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72: 491-501, 1993.